Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01100723 · ClinicalTrials.gov registry record · Phase 4

Trial to Optimize Mineral Outcomes in Dialysis Patients

A Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 4
Development phase
92
Enrollment target
1
Study location

NCT01100723 is a Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism that has completed, run by University of Colorado, Denver. The registered enrollment target is 92 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01100723, a Phase 4 study of Chronic Kidney Disease and Secondary Hyperparathyroidism, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 4
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

This trial is designed to determine if the use of a computer algorithm designed to optimize mineral outcomes in dialysis patients increases the number of patients achieving the desired target endpoints for calcium, phosphorus and parathyroid hormone.

Interventions

  • OTHER Cinacalcet, active vitamin D analogue

Study Locations (1)

Virginia

  • Lynchburg Nephrology Associates, P.L.L.C. - Lynchburg

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2010-03
Est. Completion 2011-08
Phase Phase 4

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT01100723

The ClinicalTrials.gov registry entry for NCT01100723 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Cinacalcet, active vitamin D analogue is the first listed.

NCT01100723 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT01100723 about?

NCT01100723 is a clinical study titled "Trial to Optimize Mineral Outcomes in Dialysis Patients". This trial is designed to determine if the use of a computer algorithm designed to optimize mineral outcomes in dialysis patients increases the number of patients achieving the desired target endpoints for calcium, phosphorus and parathyroid hormone.

What is the current status of trial NCT01100723?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2010-03. Estimated completion is 2011-08.

What conditions does trial NCT01100723 study?

This clinical trial studies the following conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism.

What interventions are being tested in trial NCT01100723?

The interventions under investigation include: Cinacalcet, active vitamin D analogue (OTHER).

Who is sponsoring clinical trial NCT01100723?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01100723 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.